HomeTrialNCT06581848
🔬NCT06581848ACTIVE NOT RECRUITING

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Study Summary

This study is to assess the safety and effectiveness of Elranatamab in the real-world clinical settings for the treatment of patients with multiple myeloma in Korea.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment150 participants
Primary Completion
Lead SponsorPfizer
Data Retrieved2026-04-11 02:55:53.189484+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.